TrialFrontiers in immunology2022

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.

Wei Sang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.